Company profile
PharmaRoth Labs, Inc.
OTC: ROTH · Healthcare · Medical - Pharmaceuticals
#1010 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ —GM —SS 40
v0.1 · 5/100 weight · pillars only
↑ listing tenure, return on assets · ↓ Piotroski F, market scale
Methodology →Revenue TTM
$181.6k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$91.5k
Employees
—
as of 2026-08-30
Market cap
$3.5k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$181.6k$181.6k2017
Net income-$91.5k-$91.5k2017
Operating income-$91.6k-$91.6k2017
Total assets$304.1k$304.1k2017
Liabilities$863.3k$863.3k2017
Equity-$549.5k-$549.5k2017
Revenue trend
FY2008 – FY2017 · USD
FY08
FY09
FY10
FY13
FY14
FY15
FY16
FY17
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is PharmaRoth Labs, Inc.’s revenue?
PharmaRoth Labs, Inc. booked $181.6k in FY2017 revenue, contracting 31% year over year — slower than 76% of Healthcare companies we track, at a -50.4% net margin.
Peers · Healthcare
Hemp, Inc——NuGen Medical Devices Inc.24DAbpro Holdings, Inc.14DPanacos Pharmaceuticals, Inc.——Appili Therapeutics Inc28DMedMira Inc.31DNeighbors
Clark →Key facts
CEOLuis Manuel Ornelas Lopez
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersLas Vegas, NV
ExchangeOTC: ROTH
Employees—
IPO date2009-06-16
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.